Related Experiment Video

Updated: Jun 13, 2026

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between

Alberto A Chiappori1, Hatem Soliman, William E Janssen

  • 1Department of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA. alberto.chiappori@moffitt.org

Expert Opinion on Biological Therapy
|April 28, 2010
PubMed
Abstract

Insights

INGN-225, a novel dendritic cell vaccine, shows promise for small cell lung cancer (SCLC) treatment. It is safe, elicits immune responses, and may enhance chemotherapy effectiveness in relapsed SCLC patients.

Area of Science:

  • Oncology
  • Immunotherapy
  • Vaccine Development

Background:

  • Small cell lung cancer (SCLC) presents poor response rates to standard therapies upon relapse.
  • p53 gene mutations in SCLC lead to tumoral protein overexpression, creating targets for p53-specific cytotoxic T cells.

Purpose of the Study:

  • To characterize INGN-225, a p53-modified adenovirus-transduced dendritic cell vaccine.
  • To review existing data and understand the role of INGN-225 in SCLC treatment.
  • To discuss pre-clinical, Phase I/II, and ongoing Phase II studies of INGN-225.

Main Methods:

  • Description of INGN-225 characteristics and manufacturing.
  • Review of pre-clinical and clinical trial data (Phase I/II and Phase II).
  • Assessment of safety, immune response, and treatment response in SCLC patients.

Main Results:

  • INGN-225 was well-tolerated in 54 patients (all toxicities Grade 2 or less).
  • A specific anti-p53 immune response was observed in 41.8% of patients.
  • Overall response post-INGN-225 was 51.5%; patients with a positive immune response showed higher efficacy (78.6% vs. 33%).

Conclusions:

  • INGN-225 demonstrates safety and induces a significant immune response in SCLC patients.
  • The vaccine appears to sensitize SCLC to subsequent chemotherapy.
  • Future role of INGN-225 depends on improving immune response induction and understanding chemotherapy-immunotherapy synergy.

More Related Videos

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...